Labcorp recently announced that it has begun operations at an anatomic pathology and histology (APH) laboratory in Los Angeles to expand its central laboratory capabilities.
The larger laboratory will expand capabilities such as digital pathology with the use of artificial intelligence (AI), multiplex immunohistochemistry (IHC), and other technologies to support clinical trials and precision medicine development, the firm said.
“Our larger, state-of-the-art laboratory allows us to further advance clinical trials across numerous therapeutic areas like oncology, hemato-oncology, and liver disease,” Vincent Drouillon, senior vice president of global testing services and scientific and medical affairs at Labcorp, said in a statement. “Additionally, it will enable us to increase capacity and to enhance capabilities of our APH services offering, including exploratory biomarkers, fully validated tests, international quality standards, and companion diagnostics.”
